Company Overview and News

0
SPML Infra Limited - Updates

2018-08-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SPMLINFRA 500402

0
SPML Infra Limited - Updates

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SPMLINFRA 500402

0
SPML Infra Limited - Press Release

2018-05-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SPMLINFRA 500402

0
SPML Infra Limited - Outcome of Board Meeting

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SPMLINFRA 500402

0
SPML Infra Limited - Financial Result Updates

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SPMLINFRA 500402

3
SPML Infra Limited

2018-04-16 thehindubusinessline
with its joint venture partner Om Metals Infraprojects has secured an international order from the Ministry of Food and Agriculture, Republic of Ghana, for work related to rehabilitation and completion of the Kpong left bank irrigation project in Ghana, Africa, for $32,012,453 (about ₹205 crore). The scope of work includes modification of the existing supply canal, main canal, cross regulators and installation of new distribution structures.
SPMLINFRA 500402 OMMETALS 531092 500570 TATAMOTORS TTM

41
Market Live: Sensex under pressure; TCS rebounds; Cipla, Grasim top gainers

2018-04-16 moneycontrol - 1
12:10 pm Order Win: SPML Infra Limited with its joint venture partner OM Metals Infraprojects has secured an international order from Ministry of Food and Agriculture, Republic of Ghana for the work related to rehabilitation and completion of Kpong left bank irrigation project in Ghana, Africa for USD 32 million (approximately Rs 205 crore).
SPMLINFRA 513262 500325 500402 RELIANCE TCHQY 532755 532215 511288 5225 532187 OMMETALS AXISBANK RIGD ARIHCAPM DCBBANK HDFCBANK 531092 500570 IHHHF TATAMOTORS RLNIY GRUH AXB INDUSINDBK IBN 532505 GRHFY 532843 BHEL TECHM AXBKY AXBA 532772 ICICIBANK FORTIS 511605 HDB 532174 500180 BRHTY 500103 UCOBANK Q0F SSWL TTM

0
SPML Infra Limited - Updates

2018-04-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SPMLINFRA 500402

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...